This excerpt taken from the NPSP 8-K filed Mar 14, 2007.
New Business Plan and Expense Reductions
NPS is taking the following actions to support the development of its late-stage products and create sustainable long-term value for patients and shareholders:
Dr. Coles commented, I regret that these actions will result in the loss of employment for many of our colleagues whose contributions are reflected in the companys enviable record of success in drug discovery. This includes two approved products, Sensipar and Preotact, and several promising drug candidates being developed in partnership with some of the worlds leading pharmaceutical companies. Ultimately, we believe this new plan is a prudent way for us to continue to create important new medicines for patients and value for shareholders.